Other News To Note

 BioAlliance Pharma SA, of Paris, said it received a €1 million (US$1.29 million) milestone payment, as provided in the commercialization agreement signed with partner Therabel Group for Loramyc in Europe. An additional €1 million payment is planned for the end of 2012. The milestone was triggered by approval from Italian health authorities for Loramyc, a treatment for oropharyngeal candidiasis in immunosuppressed patients.